Skip to main content
AAN.com
Editorials
July 13, 2011

Weekend high-dosage prednisone
A new option for treatment of Duchenne muscular dystrophy

August 2, 2011 issue
77 (5) 416-417

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13–20.
2.
Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005;84:843–850.
3.
Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249–255.
4.
King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68:1607–1613.
5.
Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200–206.
6.
Moxley RT, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25:1116–1129.
7.
Escolar DM, Hache LP, Clemens PA, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77:444–452.
8.
Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917–925.

Information & Authors

Information

Published In

Neurology®
Volume 77Number 5August 2, 2011
Pages: 416-417
PubMed: 21753162

Publication History

Published online: July 13, 2011
Published in print: August 2, 2011

Permissions

Request permissions for this article.

Disclosure

Dr. Moxley receives research support from the NIH (NCRR/NIAMS) and NINDS, which supports the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center; has served on scientific advisory boards for the NIH and the CDC; and has served as a consultant for Insmed, Inc. Dr. Pandya serves as a consultant for Acceleron Pharma and Shire plc and receives research support from the NIH and the CDC.

Authors

Affiliations & Disclosures

Richard T. Moxley, III, MD
From the Department of Neurology, University of Rochester Medical Center, Rochester, NY.
Shree Pandya, PT, DPT, MS
From the Department of Neurology, University of Rochester Medical Center, Rochester, NY.

Notes

Address correspondence and reprint requests to Dr. Richard T. Moxley III, Department of Neurology, Box 673, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642 [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study, Journal of Neuromuscular Diseases, 4, 3, (217-236), (2017).https://doi.org/10.3233/JND-170223
    Crossref
  2. What’s Next in the Field of Bone Health in Pediatrics? Research Considerations, Bone Health Assessment in Pediatrics, (285-313), (2016).https://doi.org/10.1007/978-3-319-30412-0_13
    Crossref
  3. Evaluation of Fracture Without Known Trauma: Use of DXA in Differential Diagnosis, Bone Health Assessment in Pediatrics, (267-283), (2016).https://doi.org/10.1007/978-3-319-30412-0_12
    Crossref
  4. Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members, International Journal of Molecular Medicine, 35, 4, (1051-1057), (2015).https://doi.org/10.3892/ijmm.2015.2084
    Crossref
  5. Clinical Management of Dystrophinopathies, Neuromuscular Disorders of Infancy, Childhood, and Adolescence, (593-619), (2015).https://doi.org/10.1016/B978-0-12-417044-5.00031-7
    Crossref
  6. Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK), European Journal of Human Genetics, 21, 10, (1049-1053), (2013).https://doi.org/10.1038/ejhg.2012.301
    Crossref
  7. Osteoporosis in Childhood and Adolescence, Osteoporosis, (1037-1086), (2013).https://doi.org/10.1016/B978-0-12-415853-5.00043-1
    Crossref
  8. Evidence‐based path to newborn screening for duchenne muscular dystrophy, Annals of Neurology, 71, 3, (304-313), (2012).https://doi.org/10.1002/ana.23528
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share